Table 3.

Persistence of AAV NAbs

Study ID (with Vector Dose in vg/kg) and Years Post-vector	AAV2 Titer	AAV5 Titer	AAV8 Titer
Subject B (8 × 1010)
9	1:100–1:1,000	1:20–1:200	1:20–1:200
10	1:100–1:1,000	1:20–1:200	1:20–1:200
11	1:100–1:1,000	1:20–1:200	1:20–1:200
12	1:100–1:1,000	1:20–1:200	1:20–1:200
13	1:100–1:1,000	1:20–1:200	1:20–1:200
14	1:1,000–1:2,000	1:20–1:200	1:20–1:200
Subject G (4 × 1011)
6	>1:3,000	1:2–1:20	1:20–1:200
7	>1:3,000	1:2–1:20	1:20–1:200
8	>1:3,000	1:2–1:20	1:20–1:200
9	>1:3,000	1:2–1:20	1:20–1:200
10	>1:3,000	1:2–1:20	1:20–1:200
11	>1:3,000	1:2–1:20	1:20–1:200
12	>1:3,000	1:2–1:20	1:20–1:200
Subject E ( 2 × 1012)
10	>1:3,000	1:100–1:1,000	1:100–1:1,000
11	>1:3,000	1:100–1:1,000	1:100–1:1,000
12	>1:3,000	1:100–1:1,000	1:100–1:1,000
13	>1:3,000	1:100–1:1,000	1:100–1:1,000
14	>1:3,000	1:100–1:1,000	1:1,000–1:3,000
15	>1:3,000	1:100–1:1,000	1:100–1:1,000

NAbs, neutralizing antibodies; vg, vector genomes.